エドガーで原本を確認する
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 21, 2024
Chromocell
Therapeutics Corporation
(Exact name of registrant as specified in its charter)
| Delaware | 001-41964 | 86-3335449 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 4400
Route 9 South, Suite
1000 Freehold, NJ |
07728 | |
| (Address of registrant’s principal executive office) | (Zip code) |
Registrant’s telephone number, including area code: 732-514-2636
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered |
||
| Common Stock, par value $0.0001 per share | CHRO | The NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
| Item 7.01 | Regulation FD Disclosure. |
On March 21, 2024, the Company issued a press release announcing the launch of its eye pain treatment program with the hiring of Dr. Simon Chandler, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in such exhibit shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release of Chromocell Therapeutics Corporation, dated March 21, 2024. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 21, 2024 | CHROMOCELL THERAPEUTICS CORPORATION | |
| By: | /s/ Francis Knuettel II | |
| Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer |
||
|
|
Exhibit 99.1
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
New Program Targets Estimated $2.5 Billion Eye Pain Market
Freehold, New Jersey — March 21, 2024 — Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell’s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications.
“The launch of our eye pain treatment program represents a significant milestone for the Company. Eye pain indications are currently under-served for treatment options, and we believe, based on the data from our programs which address various forms of systemic chronic pain using the same mechanism, that targeting NaV1.7 sodium channels in the cornea represents a viable, safe and effective treatment paradigm for eye pain,” said Frank Knuettel, CEO of Chromocell. “Moreover, the market opportunity in these under-served markets is considerable. As an example, we estimate that there are roughly 5 million corneal abrasions annually in the United States, representing an estimated market opportunity of roughly $2.5 billion.
I welcome Dr. Chandler and look forward to working with him as he guides this program towards providing much needed, effective treatment options to sufferers of eye pain in the United States and globally,” he added.
Dr. Chandler is well suited to manage the program, with over 30 years of experience in managing ophthalmic drug development programs. He has a Ph.D in Epigenetics and had a post-doctoral position at the NIH studying molecular embryology. With posts at Santen, ISTA, B&L, Allergan and Vyluma, he has successfully developed several drugs in the areas of glaucoma, and post-surgical eye pain, such as Durysta for Glaucoma and Bromday in pain and inflammation post cataract surgery.
|
|
About Chromocell Therapeutics Corp.
Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the Company intends to explore these and other compounds for the treatment of additional pain indications. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.
Forward-Looking Statements
This
press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements
include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that its portfolio
of therapeutics will be suitable for an array of eye pain indications, (ii) the Company’s belief that the market opportunity in
under-served markets is considerable and (iii) the Company's intent to explore certain compounds for the treatment of pain indications.
These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult
to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include,
but are not limited to, risks and uncertainties related to (i) the Company expending its limited resources to pursue a compound or indication
and failing to capitalize on different compounds or indications that may be more profitable or for which there is a greater likelihood
of success and the Company potentially not being successful in discovering, developing and commercializing additional compounds, (ii)
the Company needing to establish its market development capabilities to commercialize its products with the failure to do so potentially
resulting in an inability to generate any revenue, (iii) the Company facing significant competition and its competitors potentially achieving
regulatory approval before the Company or developing therapies that are more advanced or effective than the Company’s, which may
adversely affect the Company’s financial condition, (iv) the Company’s ability to obtain and maintain adequate U.S. and foreign
patent protection for its compounds, the Company facing litigation or administrative proceedings by a third-party over its patents, changes
in U.S. or foreign patent law or interpretation thereof diminishing the value of its patents, and the Company’s ability to protect
the confidentiality of its trade secrets, (v) third-parties instituting patent litigation against the Company in the U.S. or a foreign
jurisdiction asserting that CC8464 and/or additional lead compounds infringe its patent rights, the outcome of which would be uncertain
and could have a material adverse effect on the success of the Company’s business, (vi) there being no guarantee that the results
from prior clinical and preclinical studies will be indicative of the Company’s ability to complete studies or the results to be
obtained in the current or future studies and clinical trials and (vii) the Company’s ability to retain key employees and scientific
advisors and to attract, retain and motivate qualified personnel. These and other risks and uncertainties are described more fully in
the section captioned “Risk Factors” in the Company’s Registration Statement on Form S-1 (SEC File No. 333-269188).
Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Chromocell Media and Investor Inquires:
LR Advisors LLC.
Jason Assad
678-570-6791
Jason@Chromocell.com
|
|